U.S. Markets close in 5 hrs 52 mins
  • S&P 500

    3,675.05
    +6.04 (+0.16%)
     
  • Dow 30

    29,990.61
    +106.82 (+0.36%)
     
  • Nasdaq

    12,416.59
    +67.23 (+0.54%)
     
  • Russell 2000

    1,845.10
    +7.07 (+0.38%)
     
  • Crude Oil

    45.21
    -0.07 (-0.15%)
     
  • Gold

    1,836.10
    +5.90 (+0.32%)
     
  • Silver

    24.01
    -0.07 (-0.29%)
     
  • EUR/USD

    1.2168
    +0.0053 (+0.4381%)
     
  • 10-Yr Bond

    0.9280
    -0.0200 (-2.11%)
     
  • Vix

    20.97
    -0.20 (-0.94%)
     
  • GBP/USD

    1.3478
    +0.0102 (+0.7615%)
     
  • USD/JPY

    103.7730
    -0.6510 (-0.6234%)
     
  • BTC-USD

    19,345.54
    +396.29 (+2.09%)
     
  • CMC Crypto 200

    380.27
    +5.86 (+1.56%)
     
  • FTSE 100

    6,465.42
    +2.03 (+0.03%)
     
  • Nikkei 225

    26,809.37
    +8.39 (+0.03%)
     

Epizyme (EPZM) Q4 Earnings Miss Estimates, Revenues Beat

Zacks Equity Research
·4 min read

Epizyme Inc. EPZM  incurred a loss of 59 cents per share in fourth-quarter 2019, wider than the Zacks Consensus Estimate of a loss of 51 cents and the year-ago loss of 29 cents.

Quarter in Detail

Collaboration revenues in fourth-quarter 2019, earned as part of the company’s alliance with Boehringer Ingelheim, were $4.3 million compared with $9.7 million in the prior-year period. Revenues beat the Zacks Consensus Estimate of $3 million. 

Shares of Epizyme have increased 57.3% in the past year against the industry’s 5.8% decline.

 

On Jan 23, 2020, the FDA granted accelerated approval to tazemetostat for the treatment of adults and pediatric patients aged 16 years and older with metastatic or locally advanced Epithelioid Sarcoma (ES) not eligible for complete resection. It will be marketed under the brand name Tazverik. Tazverik became commercially available to patients on Feb 1, 2020.

Research and development expenses increased 75.7% year over year to $38.3 million in the quarter. The increase is due to the initiation of the global confirmatory studies in ES and FL and early expansion of the tazemetostat program into new indications and combinations

General and administrative expenses were $23.5 million in the quarter, up 92.6% from the year-ago period due to launch and commercialization of Tazverik for the ES indication, as well as initial expansion to prepare for FL commercialization in the United States.

Epizyme had $381.1 million of cash, cash equivalents and marketable securities as of Dec 31, 2019 compared with $240.3 million in the corresponding period of 2018. The company expects its cash runway to extend into at least 2022.

2019 Results

Epizyme posted a loss of $1.93 in 2019, wider than the loss of $1.72 in 2018.

Collaboration revenues in 2019 came in at$23.8 million, up 9.7% year over year.

Pipeline Update

The FDA accepted the company’s supplemental NDA (sNDA) for filing for the accelerated approval of Tazverik for a proposed indication of patients with relapsed or refractory FL who have received at least two prior lines of systemic therapy. The FDA granted Priority Review for the sNDA and set an action date of Jun 18, 2020. 

Expected Milestones in 2020

The company expects to complete the safety portion of the ongoing global, phase Ib/III confirmatory study assessing Tazverik in combination with doxorubicin compared with doxorubicin plus placebo as a front-line treatment for ES, and advance into the efficacy portion of the study.

The company also expects to complete the safety portion of the ongoing global phase Ib/III confirmatory study assessing Tazverik in combination with "R2" (Revlimid plus Rituximab) compared with Rplus placebo in the second-line treatment setting for FL and advance into the efficacy portion of the study.

Epizyme, Inc. Price, Consensus and EPS Surprise

 

Epizyme, Inc. Price, Consensus and EPS Surprise
Epizyme, Inc. Price, Consensus and EPS Surprise

Epizyme, Inc. price-consensus-eps-surprise-chart | Epizyme, Inc. Quote

Zacks Rank and Stocks to Consider

Currently, Epizyme is a Zacks Rank #3 (Hold) stock.

Some better-ranked stocks in the biotech sector include Aduro Biotech Inc. ADRO Guardant Health Inc. GH and Regeneron Pharmaceuticals Inc. REGN,  each sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Aduro’s loss per share estimates for 2020 have narrowed from 86 cents to 77 cents in the past 60 days.

Guardant’s loss per share estimates for 2020 have narrowed from $1.18 to $1.13 in the past 60 days. The company delivered a trailing four-quarter positive earnings surprise of 39.21%, on average.

Regeneron’s earnings per share estimates for 2020 have increased from $26.76 to $28.31 and from $28.61 to $28.93 for 2021 in the past 60 days. The company beat earnings estimates in three of the trailing four quarters while missed in one, delivering an average positive surprise of 1.44%.

The Hottest Tech Mega-Trend of All

Last year, it generated $24 billion in global revenues. By 2020, it's predicted to blast through the roof to $77.6 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.

See Zacks' 3 Best Stocks to Play This Trend >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Regeneron Pharmaceuticals, Inc. (REGN) : Free Stock Analysis Report
 
Aduro Biotech, Inc. (ADRO) : Free Stock Analysis Report
 
Epizyme, Inc. (EPZM) : Free Stock Analysis Report
 
Guardant Health, Inc. (GH) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research